Advertisement

Tumor Biology

, Volume 37, Issue 8, pp 10923–10934 | Cite as

TNFAIP8 overexpression: a potential predictor of lymphatic metastatic recurrence in pN0 esophageal squamous cell carcinoma after Ivor Lewis esophagectomy

  • Zhenguo Sun
  • Xiangyan Liu
  • Jee Hoon Song
  • Yulan Cheng
  • Yu Liu
  • Yang Jia
  • Stephen J. Meltzer
  • Zhou Wang
Original Article

Abstract

Esophageal squamous cell carcinoma (ESCC) has a poor prognosis due to high lymphatic metastatic recurrence rates after Ivor Lewis esophagectomy. We sought to investigate the correlation between tumor necrosis factor alpha–induced protein 8 (TNFAIP8) expression and postoperative lymphatic recurrence in patients with pN0 ESCC. One hundred twenty-two patients with pN0 ESCC undergoing Ivor Lewis esophagectomy were enrolled in this study. TNFAIP8 overexpression was found in 73 (59.8 %) tumor specimens. The 3-year lymphatic metastatic recurrence rate among TNFAIP8-overexpressing patients was significantly higher than in TNFAIP8-negative patients (p = 0.003). Multivariate Cox regression identified TNFAIP8 overexpression as an independent risk factor for lymphatic recurrence (p = 0.048). TNFAIP8 messenger RNA (mRNA) levels were significantly higher in patients with lymphatic recurrence than in patients without tumor recurrence (p = 0.019). Stable silencing of TNFAIP8 expression in ESCC-derived cells (Eca109) reduced proliferation, motility, and invasion and induced apoptosis. In addition, transient silencing of TNFAIP8 expression decreased cell motility and invasion and increased apoptosis in a second ESCC-derived cell line (KYSE150). Taken together, these findings suggest that TNFAIP8 overexpression is a potential biomarker to identify pN0 ESCC patients at higher risk of lymphatic recurrence who may benefit from adjuvant therapy.

Keywords

ESCC TNFAIP8 Tumor metastasis Metastatic recurrence RNAi 

Notes

Acknowledgments

The authors thank the Department of Pathology, Provincial Hospital Affiliated to Shandong University, for specimen collection and staining evaluation. This work is supported by grants from the National Natural Science Foundation of China (No. 81172161), Jinan Science and Technology Plan (201202041). Dr. Meltzer is the Myerberg/Hendrix Professor of Gastroenterology and an American Cancer Society Clinical Research Professor.

Compliance with ethical standards

Conflict of interests

None

Supplementary material

13277_2016_4978_MOESM1_ESM.doc (566 kb)
ESM 1 (DOC 565 kb)

References

  1. 1.
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.CrossRefPubMedGoogle Scholar
  2. 2.
    Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–50.CrossRefPubMedGoogle Scholar
  3. 3.
    Collard JM, Otte JB, Fiasse R, Laterre PF, De Kock M, Longueville J, et al. Skeletonizing en bloc esophagectomy for cancer. Ann Surg. 2001;234:25–32.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Oezcelik A, Kaiser GM, Niebel W, Sleyman C, Treckmann JW, Sotiropoulos GC, et al. Ten-year survival of esophageal cancer after an en-bloc esophagectomy. J Surg Oncol. 2012;105:284–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Song Y, Wang Z, Liu X, Jiang W, Shi M. CCR7 and VEGF-C: molecular indicator of lymphatic metastatic recurrence in pN0 esophageal squamous cell carcinoma after Ivor-Lewis esophagectomy? Ann Surg Oncol. 2012;19:3606–12.CrossRefPubMedGoogle Scholar
  6. 6.
    Hulscher JB, van Sandick JW, Tijssen JG, Obertop H, van Lanschot JJ. The recurrence pattern of esophageal carcinoma after transhiatal resection. J Am Coll Surg. 2000;191:143–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Stahl M, Budach W, Meyer HJ, Cervantes A. ESMO guidelines working group. Esophageal cancer: clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21:v46–9.CrossRefPubMedGoogle Scholar
  8. 8.
    National Comprehensive Cancer Network. NCCN clinical practice guideline in oncology (NCCN guideline): Esophageal and esophagogastric junction cancers. 2015. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site. Accessed 23 March 2015.
  9. 9.
    Akhtar J, Wang Z, Jiang WP, Bi MM, Zhang ZP. Stathmin overexpression identifies high-risk of lymphatic metastatic recurrence in pN0 esophageal squamous cell carcinoma patients. J Gastroenterol Hepatol. 2013;29:944–50.CrossRefGoogle Scholar
  10. 10.
    Godfrey TE, Raja S, Finkelstein SD, Gooding WE, Kelly LA, Luketich JD. Prognostic value of quantitative reverse transcription polymerase chain reaction in lymph node-negative esophageal cancer patients. Clin Cancer Res. 2001;7:4041–8.PubMedGoogle Scholar
  11. 11.
    Li SH, Wang Z, Liu XY. Metastasis-associated protein 1 (MTA1) overexpression is closely associated with shorter disease-free interval after complete resection of histologically node-negative esophageal cancer. World J Sug. 2009;33:1876–81.CrossRefGoogle Scholar
  12. 12.
    Patel S, Wang FH, Whiteside TL, Kasid U. Identification of seven differentially displayed transcripts in human primary and matched metastatic head and neck squamous cell carcinoma cell lines: implications in metastasis and/or radiation response. Oral Oncol. 1997;33:197–203.CrossRefPubMedGoogle Scholar
  13. 13.
    Kumar D, Whiteside TL, Kasid U. Identification of a novel tumor necrosis factor-alpha-inducible gene, SCC-S2, containing the consensus sequence of a death effector domain of fas-associated death domain-like interleukin-1 beta-converting enzyme-inhibitory protein. J Biol Chem. 2000;275:2973–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Dong QZ, Zhao Y, Liu Y, Wang Y, Zhang PX, Jiang GY, et al. Overexpression of SCC-S2 correlates with lymph node metastasis and poor prognosis in patients with non-small-cell lung cancer. Cancer Sci. 2010;101:1562–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Kumar D, Gokhale P, Broustas C, Chakravarty D, Ahmad I, Kasid U. Expression of SCC-S2, an antiapoptotic molecule, correlates with enhanced proliferation and tumorigenicity of MDA-MB 435 cells. Oncogene. 2004;23:612–6.CrossRefPubMedGoogle Scholar
  16. 16.
    Zhang C, Chakravarty D, Sakabe I, Mewani RR, Boudreau HE, Kumar D, et al. Role of SCC-S2 in experimental metastasis and modulation of VEGFR-2, MMP-1, and MMP-9 expression. Mol Ther. 2006;13:947–55.CrossRefPubMedGoogle Scholar
  17. 17.
    Liu T, Gao H, Yang M, Zhao T, Liu Y, Lou G. Correlation of TNFAIP8 overexpression with the proliferation, metastasis, and disease-free survival in endometrial cancer. Tumor Biol. 2014;35:5805–14.CrossRefGoogle Scholar
  18. 18.
    Miao Z, Zhao T, Wang Z, Xu Y, Song Y, Wu J, et al. SCC-S2 is overexpressed in colon cancers and regulates cell proliferation. Tumor Biol. 2012;33:2099–106.CrossRefGoogle Scholar
  19. 19.
    Liu T, Gao H, Chen X, Lou G, Gu L, Yang M, et al. TNFAIP8 as a predictor of metastasis and a novel prognostic biomarker in patients with epithelial ovarian cancer. Br J Cancer. 2013;109:1685–92.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Yang M, Zhao Q, Wang X, Liu T, Yao G, Lou C, et al. TNFAIP8 overexpression is associated with lymph node metastasis and poor prognosis in intestinal-type gastric adenocarcinoma. Histopathology. 2014;65:517–26.CrossRefPubMedGoogle Scholar
  21. 21.
    Zhang C, Kallakury BV, Ross JS, Mewani RR, Sheehan CE, Sakabe I, et al. The significance of TNFAIP8 in prostate cancer response to radiation and docetaxel and disease recurrence. Int J Cancer. 2013;133:31–42.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Hadisaputri YE, Miyazaki T, Suzuki S, Yokobori T, Kobayashi T, Tanaka N, et al. TNFAIP8 overexpression: clinical relevance to esophageal squamous cell carcinoma. Ann Surg Oncol. 2012;3:S589–96.CrossRefGoogle Scholar
  23. 23.
    Rice TW, Rusch VW, Ishwaran H, Blackstone EH. Worldwide esophageal cancer collaboration. Cancer of the esophagus and esophagogastric junction: data-driven staging for the Seventh Edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals. Cancer. 2010;116:3763–73.CrossRefPubMedGoogle Scholar
  24. 24.
    Akhtar J, Wang Z, Zhang ZP, Bi MM. Lentiviral-mediated RNA interference targeting stathmin1 gene in human gastric cancer cells inhibits proliferation in vitro and tumor growth in vivo. J Transl Med. 2013;11:212.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Law S, Wong J. Two-field dissection is enough for esophageal cancer. Dis Esophagus. 2001;14:98–103.CrossRefPubMedGoogle Scholar
  26. 26.
    Chen G, Wang Z, Liu XY, Zhang MY, Liu FY. Clinical study of modified Ivor-Lewis esophagectomy plus adjuvant radiotherapy for local control of stage IIA squamous cell carcinoma in the mid-thoracic esophagus. Eur J Cardiothorac. 2009;35:1–7.CrossRefGoogle Scholar
  27. 27.
    Nakagawa S, Kanda T, Kosugi S, Ohashi M, Suzuki T, Hatakeyama K. Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy. J Am Coll Surg. 2004;198:205–11.CrossRefPubMedGoogle Scholar
  28. 28.
    Hou X, Wei JC, Fu JH, Wang X, Zhang LJ, Lin P, et al. Proposed modification of the seventh American joint committee on cancer staging system for esophageal squamous cell carcinoma in Chinese patients. Ann Surg Oncol. 2014;21:337–42.CrossRefPubMedGoogle Scholar
  29. 29.
    Wang ZX, Mao T, Guo XF, Fang WT. Multimodality management of squamous cell carcinoma of thoracic esophagus. Zhonghua Wei Chang Wai Ke Za Zhi. 2013;16:815–8.PubMedGoogle Scholar
  30. 30.
    You Z, Ouyang H, Lopatin D, Polver PJ, Wang CY. Nuclear factor-kappa B-inducible death effector domain-containing protein suppresses tumor necrosis factor-mediated apoptosis by inhibiting caspase-8 activity. J Biol Chem. 2001;276:26398–404.CrossRefPubMedGoogle Scholar
  31. 31.
    Fish RJ, Kruithof EK. Short-term cytotoxic effects and long-term instability of RNAi delivered using lentiviral vectors. BMC Mol Biol. 2004;5:9.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Chen H, Wang Z, Yang Z, Shang B, Liu X, Chen G. Prospective study of adjuvant radiotherapy on preventing lymph node metastasis after Ivor-Lewis esophagectomy in esophageal cancer. Ann Surg Oncol. 2013;20:2721–6.CrossRefPubMedGoogle Scholar
  33. 33.
    Zhang HG, Hyde K, Page GP, Brand JP, Zhou J, Yu S, et al. Novel tumor necrosis factor alpha-regulated genes in rheumatoid arthritis. Arthritis Rheum. 2004;50:420–31.CrossRefPubMedGoogle Scholar
  34. 34.
    Xu WW, Li B, Lam AK, Tsao SW, Law SY, Chan KW, et al. Targeting VEGFR1- and VEGFR2-expressing non-tumor cells is essential for esophageal cancer therapy. Oncotarget. 2015;6:1790–805.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Zhenguo Sun
    • 1
    • 2
  • Xiangyan Liu
    • 1
  • Jee Hoon Song
    • 2
  • Yulan Cheng
    • 2
  • Yu Liu
    • 3
  • Yang Jia
    • 1
  • Stephen J. Meltzer
    • 2
  • Zhou Wang
    • 1
  1. 1.Department of Thoracic SurgeryProvincial Hospital Affiliated to Shandong UniversityJinanChina
  2. 2.Division of Gastroenterology, Department of Medicine and Oncology and Sidney Kimmel Comprehensive Cancer CentreThe Johns Hopkins University School of MedicineBaltimoreUSA
  3. 3.Department of PathologyProvincial Hospital Affiliated to Shandong UniversityJinanChina

Personalised recommendations